Meta-analysis to Examine Effect of Amifostine on Survival in Radiotherapy-Treated Patients

Oncology NEWS InternationalOncology NEWS International Vol 13 No 8
Volume 13
Issue 8

The 14 reports in this special supplement discuss theuse of the cytoprotectant amifostine in patients withcancer of the head and neck, esophagus, lung, andcervix, as well as those with lymphoma and acutemyelogenous leukemia. Discussions focus on thepotential of this agent to both reduce radiation sideeffects such as xerostomia and permit doseescalation of chemotherapy and/or radiotherapy.Improvements in treatment outcome and quality oflife as a result of cytoprotection are examined.

VILLEJUIF, FRANCE-After more than 25 randomizedtrials, the effect of amifostine(Ethyol) on the survival of patientstreated with radiotherapy is stillunknown. This is because most ofthe trials were neither designednor powered to detect small survivaldifferences and had followupperiods that were either short(less than 2 years) or very short (afew months), according to JeanBourhis, MD, PhD, of the departmentsof biostatistics and radiotherapy,Institut Gustave-Roussy,Villejuif, France. To assess whetherthis drug is associated with asurvival benefit in radiotherapytreatedpatients, he and his col-leagues are conducting a metaanalysisof amifostine trials.Nonmetastatic Ca Only
Selection criteria include properlyrandomized trials performedbetween 1990 and June 2002, inwhich patients were randomizedto receive radiotherapy or chemoradiotherapyplus amifostine, orto radiotherapy or chemoradiotherapywithout amifostine. Patientshad nonmetastatic head andneck, lung, or pelvic carcinomas.Updated data are being collectedfor all randomized patients frompublished and unpublished trials,and extensive checking and validationwill be done to ensure theintegrity of randomization and folonilow-up. Dr. Bourhis noted "pseudorandomization"might happenin some clinical trials.Tumor Control an Endpoint
The primary endpoint of themeta-analysis is the effect of amifostineon survival. The secondaryendpoint is effect on tumor control.The meta-analysis will includemore than 2,000 patients from 8trials of non-small-cell lung cancer,13 of head and neck cancer,and 7 of pelvic cancer. The investigatorsexpect to report results inabout 1 year.Dr. Bourhis's decision to includeunpublished trials evoked somequestions during the discussionperiod. "We are trying to avoidpublication bias in favor of positivetrials," he said. "We have to becareful not to avoid trials that havenot been published becausethe results were not exactly asexpected."

Related Videos
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.
Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.
Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.
Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.
Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.
The 12-month progression-free survival rates among patients with high-risk locally advanced cervical cancer were comparable with durvalumab plus chemoradiotherapy vs placebo plus radiotherapy.
Cervical Cancer
woman speaking with physician
Related Content